---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-021225"
form_type: "8-K"
ticker: "BOLT"
cik: "0001641281"
company_name: "Bolt Biotherapeutics, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:12:51.739004+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bolt Biotherapeutics Q1 2023 net loss $18.4M; cash $171M; BDC-1001 Phase 2 plans

## Summary
- Net loss from operations $18.4M vs $23.9M in Q1 2022; collaboration revenue $1.8M (up from $0.8M).
- Cash, equivalents, and marketable securities $171.0M as of March 31, 2023; expected to fund operations through 2025.
- R&D expenses $14.6M (down from $18.4M) due to lower manufacturing and pipeline reprioritization.
- BDC-1001 Phase 2 program to initiate in 2023 in HER2+ colorectal, endometrial, gastroesophageal, and breast cancer.
- Comprehensive BDC-1001 safety/efficacy data to be presented at ASCO 2023 on June 3.

## SEC filing metadata
- accession: 0000950170-23-021225
- form_type: 8-K
- ticker: BOLT
- cik: 0001641281
- company_name: Bolt Biotherapeutics, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641281/000095017023021225/0000950170-23-021225-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641281/000095017023021225/bolt-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-021225
- JSON: https://secwatch.observer/filing/0000950170-23-021225.json
- Plain text: https://secwatch.observer/filing/0000950170-23-021225.txt

## Key facts
- Earnings Releases
  Bolt Biotherapeutics, Inc. reported financial results for first quarter ended March 31, 2023.
  - Period: first quarter ended March 31, 2023
  - Result: reported results
  source text: Bolt Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641281/000095017023021225/0000950170-23-021225-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.